Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: A multicenter cohort study

Breast Cancer

Volumn 19, Issue 3, 2012, Pages 253-258

  Sawaki, Masataka ^a   Mukai, Hirofumi ^b   Tokudome, Nahomi ^c   Nakayama, Takahiro ^d   Taira, Naruto ^e   Mizuno, Toshiro ^f   Yamamoto, Yutaka ^g   Horio, Akiyo ^h   Watanabe, Toru ⁱ   Uemura, Yukari ^j   Ohashi, Yasuo ^j  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^f MIE UNIVERSITY HOSPITAL   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

ⁱ Hamamatsu Oncology Center   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Breast cancer; Elderly; HER 2 neu; Trastuzumab

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FUROSEMIDE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOADING DRUG DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84866407689     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0270-9     Document Type: Article

References (27)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235: 177-82. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-12. (Pubitemid 19147683)
3. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save- Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbb-2 expression in breast cancer. International (Ludwig) breast cancer study group. J Clin Oncol. 1992;10:1049-56.
4. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian breast cancer study group. J Clin Oncol. 1993;11:1936-42. (Pubitemid 23304619)
5. Ravdin PM, Chamness GC. The c-erbb-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene. 1995;159:19-27.
6. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-904. (Pubitemid 27330017)
7. RomondEH, Perez EA, Bryant J, SumanVJ,Geyer CE Jr,Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84. (Pubitemid 41464706)
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353: 1659-72. (Pubitemid 41464705)
9. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36. (Pubitemid 46039831)
10. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC ? T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC ? TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: Bcirg 006 study. Cancer Res. 2009;69:500S.
11. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001; 61(Suppl 2):58-66. (Pubitemid 33033426)
12. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13:173-83. (Pubitemid 38937119)
13. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25: 3859-65. (Pubitemid 47477261)
14. Ishihara M, Mukai H, Nagai S, Mukohara T. Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. Int J Clin Oncol. 2009;14:431-5.
15. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21: 2153-60.
16. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumabrelated cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422-8.
17. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808-15. (Pubitemid 47477254)
18. Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115: 5296-308.
19. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin i evaluation. J Clin Oncol. 2010;28:3910-6.
20. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231-8.
21. Rastogi P, Jeong J, Geyer CE, Costantino JP, Romond EH, Ewer MS, et al. Five year update of cardiac dysfunction on nsabp B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) ? paclitaxel (T) vs. AC ? T with trastuzumab(H). J Clin Oncol. 2007;25:suppl;abstr LBA513.
22. Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol. 2010;28:3407-10.
23. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumabrelated cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-33. (Pubitemid 47310891)
24. Ewer MS. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-6. (Pubitemid 46657379)
25. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience. J Clin Oncol. 2006;24:4107-15. (Pubitemid 46622286)
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45. (Pubitemid 350003059)
27. Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2 positive elderly breast cancer patients: N-SAS BC 07 (RESPECT study). Jpn J Clin Oncol. doi:10.1093/jjco/HYR011.